Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine (Nasdaq: EDIT) updated the timing of its appearance at the 2026 Jefferies Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT) updated the timing of its appearance at the 2026 Jefferies Global Healthcare Conference. The company will now present on June 4, 2026 at 2:00 p.m. ET in New York, with a live webcast and 30-day replay via its investor website.
Details
News Market Reaction – EDIT
On May 29, the first trading day after this news, EDIT closed 0.87% above the previous close.
Data tracked by StockTitan Argus for the May 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.
Updated Conference Details:
- 2026 Jefferies Global Healthcare Conference
Format: Presentation
Date: June 4, 2026
Time: 2:00 p.m. ET
New York, NY
To access the live webcast of Editas Medicine’s presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.